United Therapeutics (UTHR) stock in plain English
Every company we rate gets Strong Buy, Buy, Buy with Caution, Hold or Sell. Members see the rating for this company and the five scores behind it.
Change shown by the quote provider. Data may be delayed.
What does United Therapeutics (UTHR) do?
United Therapeutics Corp (UTHR) is a U.S.-listed company in Healthcare (Drug Manufacturers - Specialty & Generic). What it does: Develops and sells prescription drugs for severe pulmonary hypertension and lung fibrosis. Manufactures inhaled and infused therapies for rare lung diseases while developing bioengineered transplantable organs. It is worth $23.81B on the market and sold $3.19B over the last year.
- Market cap
- $23.81B
- P/E ratio
- 21.1×
- Annual sales
- $3.19B
- Sector
- Healthcare
- Industry
- Drug Manufacturers - Specialty & Generic
- Brief updated
- Nov 08, 2026
Brands and businesses behind UTHR
- Tyvaso: Inhaled treprostinil solution and dry powder sold through specialty pharmacies to treat pulmonary arterial hypertension and interstitial lung disease.
- Remodulin: Continuous subcutaneous or intravenous treprostinil formulation prescribed to reduce symptoms associated with severe pulmonary arterial hypertension.
- Orenitram: Extended-release oral treprostinil tablets prescribed to improve exercise capacity in patients living with pulmonary arterial hypertension.
- Unituxin: Monoclonal antibody injection administered in combination therapy to treat pediatric patients with high-risk neuroblastoma.
UTHR’s flags, in plain English
Each flag is a number from United Therapeutics’ reports to the SEC or from market data, with the reason it matters. This brief was updated on Nov 08, 2026.
Stupid Cash
Can pay this year's bills 4.6 times over. Cash in the bank covers a long stretch of running costs. The company can fund itself without borrowing or selling new shares.
Low debt
Low debt, only 0% of shareholder equity. The company owes very little compared with what it earns, so a bad year is less likely to force its hand.
Fat Margins
Profit margin of 38.6%. The company keeps a healthy share of each sale as profit, which gives it room when costs jump.
One Big Customer
Most commercial revenue depends on treprostinil formulations that face ongoing generic patent challenges. A large share of sales comes from a single customer. If that customer leaves or buys less, sales drop with it.
2 more green flags open with the free trial. Try it free for 7 days.
Questions about UTHR
How big is United Therapeutics?
United Therapeutics’ market cap is $23.81B: what all of its shares are worth together at today’s price. Its annual sales (revenue) are $3.19B: what customers paid the company over the last year, before any costs.
What is UTHR’s P/E ratio?
UTHR’s P/E ratio is 21.1×. Investors pay about 21.1 dollars for each dollar of the company’s yearly profit. A low number can mean a bargain or a problem, so read it next to the flags.
What could go wrong with UTHR?
The first risk note on the card is One Big Customer, explained above. A flag reads what the company reported. It does not predict the price.
Where do these numbers come from?
From United Therapeutics’ own reports to the SEC (annual and quarterly) and from market data. Every company runs through the same scoring formula, and a reviewer spot-checks cards against the source data. UTHR’s filings on SEC.gov. The Margin Monkey is research, not advice.
